Recent developments regarding human immunodeficiency virus infection and stroke

Cerebrovascular Diseases

Volumn 33, Issue 3, 2012, Pages 209-218

  Sen, Souvik ^a   Rabinstein, Alejandro A ^b   Elkind, Mitchell S V ^c   Powers, William J ^d  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Non nucleoside reverse transcriptase inhibitors; Protease inhibitor; Stroke

Indexed keywords

ANTIRETROVIRUS AGENT; NITRIC OXIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; AUTOPSY; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED STROKE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ENDOTHELIUM, VASCULAR; HIV; HIV INFECTIONS; HUMANS; RISK FACTORS; STROKE;

EID: 84855899694     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000335300     Document Type: Review

References (58)

1. Centers for Disease Control and Prevention (CDC): Prevalence of disabilities and associated health conditions among adults -United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50: 120-125.
2. Cole JW, Pinto AN, Hebel JR, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Price TR, Sloan MA, Stern BJ, Wityk RJ, Wozniak MA, Kittner SJ: Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004; 35: 51-56.
3. Ovbiagele B, Nath A: Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 2011; 76: 444-450.
4. Connor MD, Lammie GA, Bell JE, Warlow CP, Simmonds P, Brettle RD: Cerebral infarction in adult AIDS patients: Observations from the Edinburgh HIV Autopsy Cohort. Stroke 2000; 31: 2117-2126.
5. Evers S, Nabavi D, Rahmann A, Heese C, Reichelt D, Husstedt IW: Ischaemic cerebrovascular events in HIV infection: A cohort study. Cerebrovasc Dis 2003; 15: 199-205.
6. Engstrom JW, Lowenstein DH, Bredesen DE: Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. Am J Med 1989; 86: 528-532.
7. Tipping B, de Villiers L, Wainwright H, Candy S, Bryer A: Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry 2007; 78: 1320-1324.
8. Ortiz G, Koch S, Romano JG, Forteza AM, Rabinstein AA: Mechanisms of ischemic stroke in HIV-infected patients. Neurology 2007; 68: 1257-1261.
9. Corral I, Quereda C, Moreno A, Perez-Elias MJ, Dronda F, Casado JL, Muriel A, Masjuan J, Alonso-de-Lecinana M, Moreno S: Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: Incidence and risk factors. Cerebrovasc Dis 2009; 27: 559-563.
10. Cole JW, Pinto AN, Hebel JR, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Price TR, Sloan MA, Stern BJ, Wityk RJ, Wozniak MA, Kittner SJ: Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004; 35: 51-56.
11. Qureshi AI, Janssen RS, Karon JM, Weissman JP, Akbar MS, Safdar K, Frankel MR: Human immunodeficiency virus infection and stroke in young patients. Arch Neurol 1997; 54: 1150-1153.
12. Hoffmann M, Berger JR, Nath A, Rayens M: Cerebrovascular disease in young, HIV-infected, black Africans in the KwaZulu Natal province of South Africa. J Neurovirol 2000; 6: 229-236.
13. Patel VB, Sacoor Z, Francis P, Bill PL, Bhigjee AI, Connolly C: Ischemic stroke in young HIV-positive patients in Kwazulu-Natal, South Africa. Neurology 2005; 65: 759-761.
14. Rabinstein AA: Stroke in HIV-infected patients: A clinical perspective. Cerebrovasc Dis 2003; 15: 37-44.
15. Kossorotoff M, Touzé E, Godon-Hardy S, Serre I, Mateus C, Mas JL, Zuber M: Cerebral vasculopathy with aneurysm formation in HIV-infected young adults. Neurology 2006; 66: 1121-1122.
16. Jericó C, Knobel H, Calvo N, Sorli ML, Guelar A, Gimeno-Bayon JL, Saballs P, Lopez-Colomes JL, Pedro-Botet J: Subclinical carotid atherosclerosis in HIV-infected patients: Role of combination antiretroviral therapy. Stroke 2006; 37: 812-817.
17. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
18. Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC: Infectious burden and risk of stroke: The northern Manhattan study. Arch Neurol 2010; 67: 33-38.
19. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, Horsburgh CR Jr.: Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42: 1325-1332.
20. Jones SC, Radinsky CR, Furlan AJ, Chyatte D, Perez-Trepichio AD: Cortical NOS inhibition raises the lower limit of cerebral blood flow-arterial pressure autoregulation. Am J Physiol 1999; 276:H1253-H1262.
21. Schmidt JF, Waldemar G, Vorstrup S, Andersen AR, Gjerris F, Paulson OB: Computerized analysis of cerebral blood flow autoregulation in humans: Validation of a method for pharmacologic studies. J Cardiovasc Pharmacol 1990; 15: 983-988.
22. Dirnagl U, Pulsinelli W: Autoregulation of cerebral blood flow in experimental focal brain ischemia. J Cereb Blood Flow Metab 1990; 10: 327-336.
23. Schumann P, Touzani O, Young AR, Morello R, Baron JC, MacKenzie ET: Evaluation of the ratio of cerebral blood flow to cerebral blood volume as an index of local cerebral perfusion pressure. Brain 1998; 121(Pt 7): 1369-1379.
24. Powers WJ, Grubb RL Jr., Raichle ME: Physiological responses to focal cerebral ischemia in humans. Ann Neurol 1984; 16: 546-552.
25. Sillesen H, Schroeder T, Steenberg HJ, Hansen HJ: Doppler examination of the periorbital arteries adds valuable hemodynamic information in carotid artery disease. Ultrasound Med Biol 1987; 13: 177-181.
26. Derdeyn CP, Carpenter DA, Videen TO, Grubb RL Jr., Powers WJ: Patterns of infarction in hemodynamic failure. Cerebrovasc Dis 2007; 24: 11-19.
27. Seaberg EC, Benning L, Sharrett AR, Lazar JM, Hodis HN, Mack WJ, Siedner MJ, Phair JP, Kingsley LA, Kaplan RC: Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 2010; 41: 2163-2170.
28. Brilla R, Nabavi DG, Schulte-Altedorneburg G, Kemeny V, Reichelt D, Evers S, Schiemann U, Husstedt IW: Cerebral vasculopathy in HIV infection revealed by transcranial Doppler: A pilot study. Stroke 1999; 30: 811-813.
29. Ogasawara K, Ogawa A, Terasaki K, Shimizu H, Tominaga T, Yoshimoto T: Use of cerebrovascular reactivity in patients with symptomatic major cerebral artery occlusion to predict 5-year outcome: Comparison of xenon-133 and iodine-123-IMP single-photon emission computed tomography. J Cereb Blood Flow Metab 2002; 22: 1142-1148.
30. Wang X, Chai H, Yao Q, Chen C: Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44: 493-499.
31. Subsai K, Kanoksri S, Siwaporn C, Helen L, Kanokporn O, Wantana P: Neurological complications in AIDS patients receiving HAART: A 2-year retrospective study. Eur J Neurol 2006; 13: 233-239.
32. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N: Cardio-and cerebrovascular events in HIV-infected persons. AIDS 2004; 18: 1811-1817.
33. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
34. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN: Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 1145-1155.
35. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G, Pastore G: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-F128.
36. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL: Primary prevention of ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 1583-1633.
37. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr., Smith SC Jr., Stone NJ, Taubert KA: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391.
38. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
39. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
40. Touzé E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL: Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: A systematic review and meta-analysis. Stroke 2005; 36: 2748-2755.
41. Dhamoon MS, Elkind MS: Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. Circulation 2010; 121: 2071-2078.
42. Dhamoon MS, Moon YP, Paik MC, Sacco RL, Elkind MSV: The inclusion of stroke in risk stratification for primary prevention of vascular events: The Northern Manhattan Study. Stroke 2011; 42: 2878-2882.
43. Guidelines of the European AIDS Clinical Society, Version 6. Oct 2009. Available at: Http://www.europeanaidsclinicalsociety. org/images/stories/EACS- Pdf/eacsguidelines-v6-english.pdf (accessed Jan 5, 2012).
44. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD: The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218-230.
45. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, Wilson PW, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH: State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: Executive summary. Circulation 2008; 118: 198-210.
46. Hammer SM, Eron JJ Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-570.
47. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, Martinez E, Nair D, Powderly WG, Reiss P, Sutinen J, Vigano A: European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9: 72-81.
48. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Cosponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113:e409-e449.
49. Savés M, Chêne G, Ducimetiére P, Leport C, Le Moal G, Amouyel P, Arveiler D, Ruidavets JB, Reynes J, Bingham A, Raffi F: Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
50. Stein JH, Hadigan CM, Brown TT, Chadwick E, Feinberg J, Friis-Moller N, Ganesan A, Glesby MJ, Hardy D, Kaplan RC, Kim P, Lo J, Martinez E, Sosman JM: Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation 2008; 118:e54-e60.
51. Farrugia PM, Lucariello R, Coppola JT: Human immunodeficiency virus and atherosclerosis. Cardiol Rev 2009; 17: 211-215.
52. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C: Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
53. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM: Influenza vaccination as secondary prevention for cardiovascular disease: A science advisory from the American Heart Association/American College of Cardiology. Circulation 2006; 114: 1549-1553.
54. Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, Chiodo F: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19: 1051-1058.
55. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, Churchill D, Cromarty B, Das S, Fisher M, Freedman A, Geretti AM, Johnson M, Khoo S, Leen C, Nair D, Peters B, Phillips A, Pillay D, Pozniak A, Walsh J, Wilkins E, Williams I, Williams M, Youle M: British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
56. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
57. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S: Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357: 2359-2370.
58. Bozzette SA, Ake CF, Tam HK, Phippard A, Cohen D, Scharfstein DO, Louis TA: Longterm survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47: 338-341.